Dr. Galvin has been at the forefront of multidisciplinary technology commercialization since 1993, when he launched Kionix Inc. to commercialize a novel micro-electro-mechanical system (MEMS) technology platform. Dr. Galvin sold the Kionix telecommunications platform to Calient Networks Inc. in 2000 and purchased the rights to the name and access to certain markets in 2001. Dr. Galvin continued his successful commercialization of Kionix with applications in MEMS technology for semiconductor applications including a highly successful accelerometer product for smartphones. Dr. Galvin spun out Rheonix Inc. from Kionix in 2008 to capitalize on non-MEMS-based microfluidic opportunities in the molecular diagnostics industry and sold the second incarnation of Kionix Inc. to Rohm Co. Ltd.

Dr. Galvin is a member of several scientific societies, has published more than 20 technical papers and holds 58 patents. He is a member of the Advisory Councils of the Cornell Engineering College, Entrepreneurship at Cornell and the Cornell Materials Science Department and has served as a member of the Cornell Board of Trustees. He also serves as a director of the Boyce Thompson Institute for Plant Research and Ithaca Area Economic Development. He was named Cornell Entrepreneur of the Year 2014.

He holds a B.S. from the California Institute of Technology in electrical engineering and a Ph.D. in materials science and MBA from Cornell University.

Mr. Proujansky is a Managing Partner of Cayuga Venture Fund (CVF) and serves on several CVF portfolio company boards. He is also a Founding Managing Partner of Integrated Acquisition & Development Corp. (IAD), a diversified commercial real estate firm and private equity investor. Mr. Proujansky has been a Principal Investor in a number of technology-based businesses prior to CVF, including companies in the development of “non-wireline” cellular telephone MSA and RSA markets as well as in companies with expertise in artificial intelligence for industrial applications.

He began his career as a Financial Analyst and Consultant after studying Engineering Physics at Cornell University. Mr. Proujansky works in Ithaca, NY and serves on a number of advisory boards affiliated with Cornell University, the Paleontological Research Institution and several other nonprofit organizations.

Dr. Proujansky is an experienced healthcare physician executive, having served for over 30 years in physician, hospital and health system leadership positions. While at Nemours Children’s Health System, his roles included chief executive for the physician practice, chief operating officer for the Nemours Children’s Healthcare System, and chief executive for the duPont Hospital for Children and Delaware Valley Operations. He has broad experience and expertise in physician practice management, hospital operations, and statewide and regional market strategy. Dr. Proujansky has previously served as a board member of the Delaware Healthcare Association and the Delaware Health Sciences Alliance, and as a member of the Children’s Hospital Association’s Quality and Safety Committee.

Dr. Proujansky received his undergraduate and medical degrees from Northwestern University and an MBA from the University of Massachusetts. He completed training in pediatrics at the University of Connecticut and fellowships in gastroenterology and nutrition and infectious disease research at Harvard Medical School. He is a professor of pediatrics at the Sidney Kimmel College of Medicine of Thomas Jefferson University.

Dr. Nachamkin is professor emeritus of pathology and laboratory medicine and the immediate past director of the division of laboratory medicine and associate director of the clinical microbiology laboratory at the Perelman School of Medicine and Hospital of the University of Pennsylvania in Philadelphia. Dr. Nachamkin has been the principal or co-principal investigator of numerous research programs while at Penn and author or co-author of over 220 peer-reviewed papers, reviews and book chapters. He is an expert in clinical microbiology with a focus on laboratory diagnostics, molecular diagnostics in infectious diseases and laboratory management. He received his undergraduate degree in medical laboratory science from the University of Bridgeport and his MPH and DrPH from the University of North Carolina. He completed postgraduate training as a fellow in medical and public health laboratory microbiology at the Medical College of Virginia and at the Penn Medicine Clinical Leadership Academy.

Dr. Thomas is a Professor of Medicine, Professor of Microbiology & Immunology, and Infectious Diseases physician-scientist from SUNY Upstate Medical University. He is the Director, Institute for Global Health and Translational Science (IGHTS) and the interim Chair, Microbiology and Immunology. Prior to joining Upstate Dr. Thomas spent twenty years in the U.S. Army serving at the Walter Reed Army Institute of Research and completing his career as the institute’s Deputy Commander for Operations. Dr. Thomas specializes in the study of viruses and vaccine development and spent more than 5 years of his early career living and working in Thailand. He played key leadership roles in the U.S. government response to the West Africa Ebola outbreak (2014-2016) and MERS-CoV and Zika epidemics and was instrumental in the development and advancement of vaccines for each. Currently, he is the global coordinating principal investigator for Pfizer’s phase 1/2/3 COVID vaccine trial.

Dr. Thomas earned his Bachelor of Arts with Honors in Biomedical Ethics from Brown University, his Medical Degree from Albany Medical College, and completed his Internal Medicine residency and Infectious Diseases fellowship at Walter Reed Army Medical Center.